| Database ID | Agent | Target | Cancer Type | Detail |
| DB00601 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00602 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00603 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00604 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00605 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00606 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00607 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00608 | sorafenib | Vascular endothelial growth factor receptor 1 BRaf protooncogene serine/threonineprotein kinase Protooncogene tyrosineprotein kinase receptor ret | Tumors of the nervous system | view |
| DB00609 | bevacizumab sorafenib | NA | Tumors of the nervous system | view |
| DB00610 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00611 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00612 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00613 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00614 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |
| DB00615 | bevacizumab | Vascular endothelial growth factor | Tumors of the nervous system | view |